Video shuts down common ozone myth with simple explanation: 'It wasn't just a fluke'
When TikToker Emma (@simpleenvironmentalist) received a comment filled with misinformation, she knew she had to do something about it.
The commenter doubted the planet's warming. "'It's here' but ice is growing?" the commenter questioned. "It's like in the 80s — they said the ozone would be gone in…5-7 years. Guess what — it's still there."
This comment misses some crucial information, which Emma quickly pointed out.
"You wanna know why the ozone is fixed? Because we fixed it," she said, noting how many people who deny the changing climate cite the (mostly) intact ozone layer as evidence.
In 1985, a hole in the ozone layer was confirmed above Antarctica, per the United Nations Environment Programme. According to the European Environment Agency, the ozone layer sits in the stratosphere about 20 kilometers (12.4 miles) above the planet. Without it, life on Earth would be routinely exposed to the sun's harmful radiation, putting millions of people at risk of skin cancer and other issues.
Four years later, the Montreal Protocol — the only UN environmental agreement to be ratified by every country in the world — came into effect. Its goal was to phase out ozone-depleting substances.
While the Antarctic hole isn't completely mended, it's healing up nicely, and it is expected to close by 2066. That's because governments acted swiftly, reducing usage of these harmful substances by 99%.
"It wasn't just a fluke," Emma said, "It wasn't just random. It was because we quit doing stuff to harm the ozone."
The Montreal Protocol teaches a powerful lesson — people can come together to heal the planet. While many people unfortunately believe that concern over the ozone layer was a myth, climate experts are thankfully able to separate fact from fiction.
Commenters appreciated Emily's efforts.
Do you think America does a good job of protecting its natural beauty?
Definitely
Only in some areas
No way
I'm not sure
Click your choice to see results and speak your mind.
"We don't have to be literal experts in everything, but we can absolutely believe scientists' opinions in their expert fields!" one commenter said.
"It's proof we have power to fix things," another added.
Join our free newsletter for weekly updates on the latest innovations improving our lives and shaping our future, and don't miss this cool list of easy ways to help yourself while helping the planet.
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Harvard Business Review
3 hours ago
- Harvard Business Review
AI in Life Sciences
Download the Report The life sciences industry needs a shot of adrenaline. An aging population and a rise in chronic diseases are fueling the demand for highly accurate medical imaging and diagnostic tools. Pharmaceutical companies and manufacturers are under growing pressure to keep pace with supply and demand for critical medications and medical devices, respectively. Patients, meanwhile, are increasingly demanding personalized health care experiences that cater to their unique needs.
WebMD
5 hours ago
- WebMD
The Surge in Type 1 Diabetes, and the New Ways to Fight It
Aug. 19, 2025 — Cases of type 1 diabetes — an autoimmune condition where the body attacks insulin-producing beta cells — are rising faster than ever, climbing about 42% in since 1990. That's a huge increase in a disease that's expensive, incurable, and still shortens lifespan by more than a decade. But the number of new and emerging treatments is surging too, and experts say we're in the most promising era of type 1 diabetes treatments in history, with new medications that slow the disease's progression, advanced insulin delivery systems, inhalable options, and drugs that improve insulin resistance. It's a shift in the management of a chronic lifelong disease for patients who are often diagnosed in childhood. 'These patients are living much longer than they used to with an improved quality of life,' said Kupper A. Wintergerst, MD, a pediatric endocrinologist and executive director of the Wendy Novak Diabetes Institute. Experts attribute the rise in type 1 cases to a few factors. Genetics play a role in who will get type 1 diabetes, increasing a patient's risk by about 40%. And in people with an increased risk, certain environmental factors may serve to nudge them toward getting the disease. For example, infections in early childhood like mumps, rubella, and influenza B as well as childhood obesity and certain environmental factors like antibiotics overuse, vitamin D deficiency, and the hygiene hypothesis — which suggests that kids who aren't exposed to enough microorganisms in childhood may end up with an overactive immune system — may also be playing a role. Additionally, certain chemicals found in foods and drinking water, including PFAS, dioxins, and arsenic, may jolt inflammation in the body. Once these chemicals build up in the bloodstream, it triggers a chronic inflammatory state, which contributes to the immune system mistakenly attacking and destroying its own insulin-producing beta cells in the pancreas. Over time, this lack of beta cells causes the body to stop making insulin, which starts to raise blood sugar. Researchers are responding with new treatment strategies that leverage a slowed progression of the disease while also more accurately monitoring and regulating blood sugars, which all work to extend lifespan. The number of patients living past 65 has tripled in the last four decades. Slowing Progression of the Disease Type 1 diabetes is usually diagnosed in childhood, though it can develop in adulthood, too. A new medication, called teplizumab (Tzield), has been shown to slow the disease's progression, potentially staving off the disease for two or three years. It's now for patients either before they're diagnosed or early after a diagnosis. Once patients have tested positive for two or more type 1 diabetes-related autoantibodies, they're considered eligible for the medicine. They may also have abnormal blood sugar levels but don't yet have other symptoms of type 1 diabetes like excessive thirst, frequent urination, slowed wound healing, and excessive hunger. The medication works by binding to CD3 proteins on the surface of the white blood cell, helping to block the autoimmune attack. The medication must be started a few weeks or months after diagnosis. While it's not good for all patients, it can be helpful especially for children in staving off this life-altering condition for up to three more years of childhood. 'For patients who are early on in their type 1 disease, this medication can help prolong the beta cell function that is remaining and decrease how much insulin a person needs, depending on when it's used in their disease course,' said Bethany L. Gottesman, MD, a pediatric endocrinologist at Phoenix Children's in Phoenix, Arizona. Patients need to visit a facility that offers infusion services over the weekend. These infusion centers are available throughout the country. You can also contact the TZIELD COMPASS Support Program to find a center near you. Beyond slowing the progression of the disease, the next step would be preserving beta cell function indefinitely, which would prevent the disease. Stem cell-derived beta cells are designed to mimic the function of natural beta cells, restoring function to damaged cells before the damage can to type 1 diabetes. A stem cell-derived treatment called zimislecel has shown promising results in early trials, but it is about a decade away from being available to patients, according to experts. Improved Insulin Delivery Systems Science has revolutionized insulin delivery systems, which now do a much better job of mimicking the pancreas — because they measure sugars beneath the skin and between cells and communicate with the insulin pump. A sensor inserted just beneath the skin measures the interstitial fluid that surrounds cells. After that, software built into the device analyzes the glucose data, sending a message to the insulin pump to deliver insulin through a small needle that penetrates the skin. The data gathered from the cells is transmitted wirelessly to a smartphone or directly to an insulin pump. 'As sugar levels rise or fall, the pump can respond by decreasing or increasing the amount of insulin that's delivered through an algorithm,' said Wintergerst. The algorithm is the computer programming process that tells the glucose monitoring system when more insulin is required, all based on data it's collected on blood sugar in the body as well as other potential inputs such as how many carbohydrates a person consumes. The system can provide extra insulin, for example, if it looks like a patient's blood sugar is going to spike. Still, these insulin delivery systems require the user to input the size of a meal or the amount of carbohydrates that a patient is consuming in order to know whether blood sugar is going to go up or go down in the near future, which can make it more difficult for young children. Experts contend that these more optimized systems help patients deal with type 1 diabetic burnout — when people with diabetes become mentally and physically exhausted as a result of all the demands that are put on them in terms of diet and glucose monitoring. This can be a concerning issue especially among children with diabetes who are new to the disease and must tend to their blood sugar for years to come, said Michael Yafi, MD, director of the Pediatric Endocrinology Division at McGovern Medical School at The University of Texas Health Science Center in Houston. When patients are better able to monitor their condition with ease, they're more likely to be able to stay on track with their blood sugar. This way they'll avoid experiencing the organ damage caused by elevated blood sugars, which over time damages the body's blood vessels and nerves, leading to blurred vision, kidney failure, neuropathy, and early death as the body's systems break down. Inhaled Insulin for Both Kids and Adults The inhaled insulin Afrezza provides rapid delivery of insulin to patients after a meal or after exercise to help stabilize blood sugar levels. People with type 1 diabetes will still need insulin injections or an insulin pump to provide a steady, continuous supply of insulin for longer periods of time, but inhaled insulin can provide additional help for people who need a boost of insulin after eating a meal. It can also reduce the risk of hypoglycemia or low blood sugar after exercise because it's faster acting than the injectable version. For example, in patients who eat carbohydrates before exercise to prevent the low blood sugar that impacts their performance, it can keep the body from overcompensating and causing high blood sugar. Afrezza has already been approved for adults and is likely to be approved for children by the end of 2025, giving patients additional options while also easing some of the needle fatigue. Still, it does have its drawbacks, said Gottesman. 'It's not meant to be used if you have lung disease, and some pediatric patients have asthma. This is also true of older patients with type 1 diabetes, who are more likely to have other lung diseases,' she said. Gottesman added that the insulin only comes in set doses, which for the youngest children might not be appropriate. It's typically not as exact as rapid-acting injections. Inhaled versions of insulin provide a convenience factor for patients. It's also discreet for children who are embarrassed by their condition or don't want to inject themselves with needles in public places like at school. Newer versions of inhaled insulin are also in development, perhaps supplying a version of insulin that's liquid rather than powder, which would reduce respiratory irritation. Aerami Therapeutics has a liquid formulation in development, though it's unclear when it will be ready for the public. GLP-1s for Type 1 Diabetes With Insulin Resistance It might seem obvious: In type 1 diabetes, the problem is lack of insulin production. In type 2, it's insulin resistance – the body still makes insulin but can't use it effectively. But that clear-cut distinction doesn't always hold. Many people, including children, with type 1 diabetes develop insulin resistance, too. Despite lacking natural insulin, their bodies can become resistant to the insulin they do receive, for a number of reasons including excess weight, medications, smoking, puberty, and pregnancy. This overlap has led researchers to explore treatments once thought to be reserved only for type 2 diabetes — including GLP-1 medicines like Ozempic and Wegovy — to help patients drop excess weight and stave off or improve insulin resistance, said Alexandra De Lellis, a nurse practitioner at Parkview Endocrinology in Fort Wayne, Indiana. While type 1 diabetes is mostly an autoimmune disease, insulin resistance can be a secondary issue that causes additional complications when the body resists insulin, causing an increase in the amount of insulin required for patients. This happens when the cells don't react efficiently to insulin as a result of excess body weight, a genetic predisposition, or certain medications. 'Insulin resistance plays a large role especially for type 1 patients diagnosed in adulthood but also those who were diagnosed younger,' said De Lellis. It can be frustrating for these patients who feel like their insulin isn't having the impact it should because the body is resisting it. A study published this year in Frontiers in Endocrinology found that GLP-1s were a 'potential adjunctive therapy in [type 1 diabetes] to reduce weight and improve insulin resistance.' Studies have shown that GLP-1s can reduce blood sugars levels by between by 0.21% and 0.96%, while also reducing weight and the amount of insulin that's required of type 1 patients.
Medscape
6 hours ago
- Medscape
Diagnosis of Renal Cell Carcinoma: 5 Things to Know
Renal cell carcinoma (RCC), the most common form of kidney cancer, accounts for approximately 90%-95% of all primary renal malignancies. When diagnosed at an early, localized stage, RCC carries a favorable prognosis with a 5-year relative survival rate of 93%. However, survival drops significantly with disease progression, falling to approximately 75% for regional disease and just 18% for metastatic disease, underscoring the importance of early diagnosis. Because RCC often remains asymptomatic in its early stages, it is frequently discovered incidentally or goes undetected until progression occurs. Routine CT screening for RCC is neither practical nor cost-effective, prompting interest in more efficient, targeted diagnostic strategies. Advances in imaging and the integration of artificial intelligence (AI) are helping clinicians detect RCC earlier and with greater accuracy. Here are five things to know about the diagnosis of RCC and the evolution of diagnostic technologies. 1. Imaging is the cornerstone of RCC diagnosis. Up to 60% of RCCs are discovered incidentally, most often during abdominal imaging — particularly CT scans — performed for unrelated indications. Patients with incidentally discovered RCC tend to have better outcomes than those diagnosed after symptom onset, as incidental detection is more likely to identify tumors at a surgically resectable and nonmetastatic stage. Cross-sectional imaging, particularly contrast-enhanced CT, remains the primary modality for evaluating suspected RCC and is used routinely for both diagnosis and post-treatment surveillance. CT provides high-resolution assessments of tumor morphology, enhancement patterns, size, location, and venous invasion — information that is critical for accurate staging and surgical planning. MRI is an important alternative when CT is contraindicated, such as in patients with renal insufficiency or iodine allergy, or when CT findings are inconclusive. MRI offers excellent soft-tissue contrast and is particularly useful for delineating tumor extension into the renal vein or inferior vena cava. Multiparametric MRI enhances evaluation by generating high-resolution images that help differentiate benign from malignant masses and reveal tumor-specific characteristics, such as vascularity or cellular density, that may aid in subtype classification. Ultrasonography is a useful first-line tool in the evaluation of renal masses, particularly for distinguishing cystic from solid renal lesions. While it lacks the sensitivity and spatial resolution of CT or MRI — especially for small or isoechoic tumors — it is noninvasive, cost-effective, and widely available, making it a practical choice for routine imaging. It is particularly effective in the initial characterization of simple renal cysts and monitoring Bosniak category I and II lesions. Advanced CT technologies are enhancing the characterization of renal lesions while reducing radiation exposure and contrast-agent requirements. In centers where available, dual-energy CT allows quantification of iodine content, which can help differentiate enhancing solid masses from cystic or nonenhancing lesions. It also enables virtual unenhanced imaging, potentially eliminating the need for noncontrast scans. Photon-counting CT improves spatial resolution and material decomposition, which may aid in detecting subtle renal lesions. Early clinical studies show it offers image quality and lesion conspicuity comparable to, or exceeding, conventional CT and MRI. PET/CT with tracers such as 18F-FDG, 124I-girentuximab, and PSMA-targeted agents (eg, 68Ga-PSMA) are under investigation for both diagnosis and treatment monitoring in RCC. These molecular imaging tools have shown promise for detecting primary tumors and metastatic disease. The phase 3 ZIRCON trial showed that 89Zr-girentuximab PET/CT achieved 85% sensitivity and 87% specificity for identifying clear-cell RCC. Bone scans are typically reserved for patients with bone pain or elevated alkaline phosphatase levels suggestive of skeletal metastases. PET/CT with 18F-FDG may aid in staging and treatment response assessment, particularly in aggressive or metabolically active RCC subtypes, although their utility varies depending on RCC subtype and metabolic activity. 2. AI is enhancing imaging interpretation. AI is becoming increasingly integrated into RCC diagnosis, particularly in the analysis of CT and MRI scans. AI algorithms can help radiologists identify and characterize renal masses with high accuracy, helping to distinguish benign from malignant lesions and potentially reducing unnecessary biopsies. Radiomics, a subfield of AI, extracts and analyzes high-dimensional imaging features not visible to the human eye. Radiomics-based models have been used to classify RCC subtypes, predict tumor behavior, and support prognostic and treatment decisions, especially in complex or ambiguous cases. AI can also automate nephrometry scoring systems, which quantify renal tumor complexity based on parameters such as size, location, and proximity to critical structures. These scores guide surgical decision-making, including the feasibility of partial nephrectomy. Automated systems may help reduce inter-reader variability and streamline preoperative planning. 3. Laboratory testing aids the initial evaluation. While imaging is essential, laboratory studies play a critical role in the initial evaluation and ongoing management of patients with RCC. In patients presenting with hematuria, flank pain, unexplained weight loss, or systemic findings, recommended laboratory tests typically include: Urinalysis, with urine cytology if a centrally located lesion suggests possible urothelial carcinoma Complete blood cell count with differential Serum electrolytes and renal function tests (eg, creatinine, blood urea nitrogen) Liver function tests (aspartate aminotransferase, alanine aminotransferase), which may be abnormal in the presence of paraneoplastic Stauffer syndrome Serum calcium to assess for hypercalcemia, a common paraneoplastic finding RCC is associated with several paraneoplastic syndromes, including: Hypercalcemia (due to ectopic parathyroid hormone-related protein production) Erythrocytosis (from ectopic erythropoietin secretion) Stauffer syndrome, a reversible nonmetastatic hepatic dysfunction Identifying these laboratory abnormalities can support a diagnosis of RCC, guide further testing, and influence management decisions, especially in advanced or atypical presentations. 4. Biopsy may be needed in select cases. Although RCC is often diagnosed based on imaging findings, biopsy remains an important tool in select cases, particularly when imaging findings are inconclusive, histologic confirmation is required prior to treatment, or active surveillance is being considered. The choice of biopsy technique depends on tumor size, tumor location, patient comorbidities, and the specific clinical context. Common approaches include: Percutaneous core needle biopsy: This is typically performed under CT or ultrasound guidance. It is the most frequently used method for renal biopsy, provides tissue for histopathologic and immunohistochemical analysis, and carries a low complication rate. Fine-needle aspiration (FNA): FNA may be used to obtain cytologic material. FNA is often used as an adjunct to core biopsy; it is less definitive when used alone. Laparoscopic or surgical biopsy: This may be necessary when percutaneous biopsy is not feasible, such as with deep or anatomically challenging tumors or when larger tissue samples are needed for molecular profiling. Liquid biopsy approaches — including analysis of circulating tumor DNA, circulating tumor cells, or other biomarkers — are currently investigational but may offer future utility in RCC diagnosis, prognosis, and treatment monitoring, particularly for identifying minimal residual disease or recurrence. Histologic analysis can confirm the diagnosis of RCC, distinguish between subtypes (eg, clear cell, papillary, chromophobe), and help determine the prognosis and treatment strategy. 5. Accurate staging and grading inform the diagnosis and prognosis. Staging and grading are essential components of the RCC diagnostic process. Together, they inform prognosis, guide treatment selection, and determine eligibility for surgical or systemic therapy. Staging follows the TNM system and assesses: Tumor size and local extent (T) Regional lymph node involvement (N) Presence of distant metastases (M) Grading evaluates the tumor's cellular features to estimate its aggressiveness. While the older Fuhrman grading system may still appear in some contexts, most institutions now use the ISUP/WHO grading system, which assesses nuclear characteristics in clear-cell and papillary RCC. Final stage and grade are based on the integration of imaging findings and histologic evaluation from biopsy or surgical specimens. These metrics are critical for risk stratification and treatment planning, including decisions regarding active surveillance, nephrectomy, or systemic therapy.
